| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/31/2007 | WO2007022964A3 Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors |
| 05/31/2007 | WO2007022956A3 Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| 05/31/2007 | WO2007021795A3 Compounds and compositions as protein kinase inhibitors |
| 05/31/2007 | WO2007021666A3 Liquid formulations |
| 05/31/2007 | WO2007019549A3 Composition and method for use in cartilage affecting conditions |
| 05/31/2007 | WO2007019255A3 Salts of vildagliptin |
| 05/31/2007 | WO2007019251A3 Sphingosine kinase inhibitors and methods of their use |
| 05/31/2007 | WO2007017687A3 Ep2 receptor agonists |
| 05/31/2007 | WO2007017652A3 Arylakylamines for the treatment of cancer |
| 05/31/2007 | WO2007017248A3 Itraconazole compositions with improved bioavailability |
| 05/31/2007 | WO2007016650A3 M3 muscarinic acetylcholine receptor antagonists |
| 05/31/2007 | WO2007016525A3 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| 05/31/2007 | WO2007014941A8 Quinoline derivatives as antibacterial agents |
| 05/31/2007 | WO2007014851A3 Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
| 05/31/2007 | WO2007014469A8 Hepatitis c antivirals |
| 05/31/2007 | WO2007014393A3 Amorphous efavirenz and the production thereof |
| 05/31/2007 | WO2007013896A3 Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| 05/31/2007 | WO2007013047A3 Water-dispersible anti-retroviral pharmaceutical compositions |
| 05/31/2007 | WO2007013032A3 Method of obtaining a natural hydroxytyrosol-rich concentrate from olive tree residues and subproducts using clean technologies |
| 05/31/2007 | WO2007012968A3 Stable dosage form of an antidepressant |
| 05/31/2007 | WO2007010499A3 Derivatives of monosaccharides for the treatment of copd and allergic rhinitis |
| 05/31/2007 | WO2007010498A3 Compositions for reducing the incidence of drug induced arrhythmia |
| 05/31/2007 | WO2007010089A3 Cancer specific glycans and use thereof |
| 05/31/2007 | WO2007009080A3 Ppar [alpha/gamma] agonists and processes of preparing |
| 05/31/2007 | WO2007005633A3 Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| 05/31/2007 | WO2007003957A3 Steroidal glycoside compounds as core 2 glcnac- t inhibitors |
| 05/31/2007 | WO2007001883A3 Method to reduce oxidative damage and improve mitochondrial efficiency |
| 05/31/2007 | WO2006136419B1 Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases |
| 05/31/2007 | WO2006133198A3 Hsv drugs |
| 05/31/2007 | WO2006116862A9 Method for inhibiting er stress-induced apoptosis |
| 05/31/2007 | WO2006116458A3 Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
| 05/31/2007 | WO2006116435A3 Methods of treating atherosclerosis |
| 05/31/2007 | WO2006113552A3 Cyanoarylamines |
| 05/31/2007 | WO2006113483A3 Methods and compositions for treating or preventing cancer |
| 05/31/2007 | WO2006110491B1 Complementary compositions to reduce blood glucose levels and treat diabetes |
| 05/31/2007 | WO2006109091A3 Sensitisation of cancer cells to dna replication inhibitors |
| 05/31/2007 | WO2006106514A3 Electrospun dosage form and method of producing the same |
| 05/31/2007 | WO2006102163A3 Transfection reagents for non-adherent suspension cells |
| 05/31/2007 | WO2006098852A3 Hydroxyalkyl substituted imidazoquinolines |
| 05/31/2007 | WO2006091568A3 Hydroxyalkyl substituted imidazonaphthyridines |
| 05/31/2007 | WO2006091567A3 Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| 05/31/2007 | WO2006089161A3 Immunostimulating polyphosphazene compounds |
| 05/31/2007 | WO2006088958A3 Encapsulated (chelate or ligand) dendritic polymers |
| 05/31/2007 | WO2006088753A3 Method for decreasing cartilage damage in dogs |
| 05/31/2007 | WO2006084056A3 Compounds and methods for modulating communication and virulence in quorum sensing bacteria |
| 05/31/2007 | WO2006076021A3 Cd44 variants as therepeutic targets |
| 05/31/2007 | WO2006073715A3 Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis |
| 05/31/2007 | WO2006067312A3 Painkilling association comprising a dihydroimidazopyrazine derivative |
| 05/31/2007 | WO2006066154A3 Casein kinase 2 antisense therapy |
| 05/31/2007 | WO2006062731A8 Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye |
| 05/31/2007 | WO2006060192A3 Pyrazole derivatives |
| 05/31/2007 | WO2006050732A3 Lna oligonucleotides and the treatment of cancer |
| 05/31/2007 | WO2006047716A3 Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease |
| 05/31/2007 | WO2006045010A3 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| 05/31/2007 | WO2006042418A9 Antiviral oligonucleotides |
| 05/31/2007 | WO2006039215A3 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) |
| 05/31/2007 | WO2006033693A3 Methods of selectively treating diseases with specific glycosaminoglycan polymers |
| 05/31/2007 | WO2006014781A3 Compositions containing policosanol and biotin and their pharmaceutical uses |
| 05/31/2007 | WO2006004937A3 Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders |
| 05/31/2007 | WO2005099688A3 Cyclic compounds |
| 05/31/2007 | WO2005094802A3 Inhibiting proliferation of neoplastic cells by mlk inhibition |
| 05/31/2007 | WO2005089106A3 Degradable nanoparticles |
| 05/31/2007 | WO2005077005A3 Enhancing the effectiveness of an inhaled therapeutic gas |
| 05/31/2007 | WO2005032483A3 Polysaccharides for pulmonary delivery of active agents |
| 05/31/2007 | WO2005021733A3 Methods and compositions for sirna expression |
| 05/31/2007 | WO2005017484A3 Methods for identifying compounds for regulating muscle mass or function using dopamine receptors |
| 05/31/2007 | WO2004100882A3 Inhibition of drug binding to serum albumin |
| 05/31/2007 | WO2003089601A3 3-deoxyglucosone and skin |
| 05/31/2007 | WO2002094185A3 Conjugates and compositions for cellular delivery |
| 05/31/2007 | US20070124837 Desaturase genes, enzymes encoded thereby, and uses thereof |
| 05/31/2007 | US20070124083 Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
| 05/31/2007 | US20070123718 Novel 4-amino-2(5H)-furanones |
| 05/31/2007 | US20070123706 Method for producing 3-amidinophenylalanine derivatives |
| 05/31/2007 | US20070123704 7alpha-biscarbonyl-substituted steroid compounds |
| 05/31/2007 | US20070123696 G-csf conjugates |
| 05/31/2007 | US20070123593 Pharmaceutical composition comprising 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid |
| 05/31/2007 | US20070123592 Terephthalamide peptidomimetic compounds and methods |
| 05/31/2007 | US20070123591 Gabapentin analogues and process thereof |
| 05/31/2007 | US20070123590 Passage of a salt of gabapentin through a ionic exchange resin of strong cationic type and elution by a mineral acid such as anaqueous solution of ammonia and sodium hydroxide |
| 05/31/2007 | US20070123589 Method for producing chiral or enantiomer-enriched beta-amino acids, aldehydes, ketones and gama-amino alcohols |
| 05/31/2007 | US20070123588 Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements |
| 05/31/2007 | US20070123587 Prodrugs of diaryl-2-(5h)-furanone cyclooxygenase-2 inhibitors |
| 05/31/2007 | US20070123586 Nitroso derivatives of diphenylamine |
| 05/31/2007 | US20070123585 Nitroglycerin therapy for those unable to metabolize nitroglycerin |
| 05/31/2007 | US20070123584 Method of treating premenstrual dysphoric disorder with escitalopram |
| 05/31/2007 | US20070123583 Using low dose of a microtubule stabilizing agent such as taxol; prevents artery blockage while minimizing any negative side effects |
| 05/31/2007 | US20070123582 Crystalline form of a drug |
| 05/31/2007 | US20070123581 Coupling, hydrogenation, catalysis; reacting benzyl indole-2-carboxylate with acid and alanine compound; amidation, salt formation |
| 05/31/2007 | US20070123580 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 05/31/2007 | US20070123579 Process for preparing a dipeptidyl peptidase iv inhibitor and intermediates employed therein |
| 05/31/2007 | US20070123578 Hexahydro-cycloheptapyrazole cannabinoid modulators |
| 05/31/2007 | US20070123577 Inhibitor of protein modification products formation |
| 05/31/2007 | US20070123576 Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation |
| 05/31/2007 | US20070123575 Ep4 receptor antagonists |
| 05/31/2007 | US20070123574 Methods for the preparation of benzoxazole sulfonamide compounds and intermediates thereof |
| 05/31/2007 | US20070123573 Process for the preparation of biologically active tetrahydrobenzthiazole derivative |
| 05/31/2007 | US20070123572 Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines |
| 05/31/2007 | US20070123571 Use of a compound in the treatment of sleep disorders |
| 05/31/2007 | US20070123570 Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
| 05/31/2007 | US20070123569 Therapeutic methods using prostaglandin ep4 agonist components |